drugset / Trial / NCT00836602

Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects

NCT00836602 ↗

Phase 1 Completed 25 enrolled Bristol-Myers Squibb
RandomizedParallel-groupTriple-blindBasic science

Summary

The primary purpose of this study is to evaluate the safety and tolerability of multiple oral doses of BMS-779788 in healthy subjects

Timeline

Start
2009-02
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator BMS-779788 Small molecule 1 mg Oral
Comparator BMS-779788 Small molecule 2 mg Oral
Comparator BMS-779788 Small molecule 4 mg Oral

Indications